Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1 injection combined with golarelimab in KRAS G12C-mutant advanced or metastatic non-small cell lung cancer
CTR20263560Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan, glecirasib in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
izalontamab brengitecanglecirasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263560.